Tuesday, January 21, 2025 11:24:55 PM
zero82,
“Cash attached” will be determined by the combo efficacy in clinical trials. You keep reposting your same weak shortsighted arguments over and over daily, as if certain corporate players (or market manipulators) can somehow override or overpower the gravitational forces of science indefinitely…
Consider that PD1 blockade and other immunotherapy technologies already have a massive foothold in the relatively new and rapidly expanding global immunotherapy market. Those forces span the globe and across all big pharma companies—they are forces greater than the market influence of any individual company alone. If dendritic cell technology proves effective in overcoming tumor resistance and unlocking the full potential efficacy of other technologies, such as PD1 blockade—which is already highly profitable—then DC technologies will secure a sizable share of the market too. The only way to stop the success of DC technologies would be to stop the sale of every other technology that is synergistically efficacious in combo with dendritic cell platforms.
“Big Pharma” may have significant power, but even they are at the mercy of the power of science, just like everyone else on Earth.
⭐️Combo is King!⭐️
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175690655
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175399357
“Cash attached” will be determined by the combo efficacy in clinical trials. You keep reposting your same weak shortsighted arguments over and over daily, as if certain corporate players (or market manipulators) can somehow override or overpower the gravitational forces of science indefinitely…
Consider that PD1 blockade and other immunotherapy technologies already have a massive foothold in the relatively new and rapidly expanding global immunotherapy market. Those forces span the globe and across all big pharma companies—they are forces greater than the market influence of any individual company alone. If dendritic cell technology proves effective in overcoming tumor resistance and unlocking the full potential efficacy of other technologies, such as PD1 blockade—which is already highly profitable—then DC technologies will secure a sizable share of the market too. The only way to stop the success of DC technologies would be to stop the sale of every other technology that is synergistically efficacious in combo with dendritic cell platforms.
“Big Pharma” may have significant power, but even they are at the mercy of the power of science, just like everyone else on Earth.
⭐️Combo is King!⭐️
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175690655
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175399357
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
